ADMA Biologics' Financial Health and Insider Trading Insight

Core Insights - ADMA Biologics is a significant player in the medical sector, focusing on specialty plasma-derived products [1] - Recent insider trading by director Steve Elms indicates confidence in the company's future [1][6] Financial Performance - ADMA Biologics showcases strong financial health with net margins of 28.8%, return on equity of 37.52%, and return on assets of 27.87%, highlighting profitability and resource efficiency [2] - The company maintains a low debt-to-equity ratio of 0.17, indicating a conservative approach to debt management [5] - A strong current ratio of 6.71 demonstrates robust liquidity, ensuring the company can meet short-term liabilities [5] Market Valuation - ADMA's market valuation is reflected in its price-to-earnings (P/E) ratio of 24.45, price-to-sales ratio of 7.05, and enterprise value to sales ratio of 7.03, indicating investor willingness to pay for its earnings and sales [4] - The enterprise value to operating cash flow ratio is high at 71.19, reflecting its valuation relative to cash flow [4] Ownership Structure - Institutional investors hold 75.7% of ADMA's shares, indicating strong confidence in the company's long-term growth potential [3] - Insider ownership is at 3.7%, which is lower than Rezolute's 14.8%, suggesting a more significant role of institutional investors in ADMA's ownership structure [3]